Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 63Breast Neoplasms 63Carcinoma, Non-Small-Cell Lung 39Triple Negative Breast Neoplasms 29Ovarian Neoplasms 25Fallopian Tube Neoplasms 22Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 16Stomach Neoplasms 11Neoplasm Metastasis 11Neoplasms 9Inflammatory Breast Neoplasms 9Breast Neoplasms, Male 9Melanoma 7Esophageal Neoplasms 7Cholangiocarcinoma 7Uterine Cervical Neoplasms 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Carcinoma, Ovarian Epithelial 6Pancreatic Adenocarcinoma 5Gallbladder Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Prostatic Neoplasms 3Peritoneal Neoplasms 3

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Breast Carcinoma × Taxes × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡